{"filing":{"accession_number":"0001345099-26-000066","cik":"0001345099","ticker":"MEOBF","company_name":"MESOBLAST LTD","form":"6-K","filing_date":"2026-07-14","report_date":null,"primary_document":"form6-kxpressreleasecoverf.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1345099/000134509926000066/form6-kxpressreleasecoverf.htm"},"events":[{"id":17744,"run_id":15909,"accession_number":"0001345099-26-000066","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Mesoblast announced achievement of its target enrollment of 300 patients in the MSB-DR004 pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain. This is a material clinical development milestone—the trial is now fully enrolled and powered for success, with top-line results expected in mid-2027. The announcement indicates progress toward a potential blockbuster indication (\u003eUS$10 billion peak revenue potential) and positions the company for regulatory filing. While this is an operational/clinical milestone rather than a discrete event like M\u0026A or exec change, it materially affects investor assessment of the company's pipeline and commercial prospects.","company_name":"MESOBLAST LTD","ticker":"MEOBF","filing_date":"2026-07-14","form":"6-K","submitted_at":null,"items":[{"id":16333,"accession_number":"0001345099-26-000066","item_number":"EX-99.1","item_title":"exhibit991clbppivotaltri.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Mesoblast announced achievement of its target enrollment of 300 patients in the MSB-DR004 pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain. This is a material clinical development milestone—the trial is now fully enrolled and powered for success, with top-line results expected in mid-2027. The announcement indicates progress toward a potential blockbuster indication (\u003eUS$10 billion peak revenue potential) and positions the company for regulatory filing. While this is an operational/clinical milestone rather than a discrete event like M\u0026A or exec change, it materially affects investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:55:39.846128+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16333,"accession_number":"0001345099-26-000066","item_number":"EX-99.1","item_title":"exhibit991clbppivotaltri.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Mesoblast announced achievement of its target enrollment of 300 patients in the MSB-DR004 pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain. This is a material clinical development milestone—the trial is now fully enrolled and powered for success, with top-line results expected in mid-2027. The announcement indicates progress toward a potential blockbuster indication (\u003eUS$10 billion peak revenue potential) and positions the company for regulatory filing. While this is an operational/clinical milestone rather than a discrete event like M\u0026A or exec change, it materially affects investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:55:39.846128+00:00","company_name":"MESOBLAST LTD","ticker":"MEOBF","filing_date":"2026-07-14"}]}